Adam Burdorf
University of Nebraska Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Adam Burdorf.
The VAD Journal | 2018
Scott Lundgren; Elizabeth Lyden; Douglas Stoller; Marshall Hyden; Adam Burdorf; Ronald Zolty; John Um; Brian D. Lowes
Left ventricular assist devices (LVAD) are an increasingly used therapy for patients with advanced heart failure. Arrhythmias are common complications following LVAD implantation requiring admission, initiation, and escalation of medical therapy. Despite their frequent use in the treatment of arrhythmias, little has been reported regarding electrocardiographic changes, antiarrhythmic utilization, and outcomes post-LVAD.
International Journal of Artificial Organs | 2018
Scott Lundgren; Cecilia Y.M. Poon; A. Selim; Brian D. Lowes; Ronald Zolty; Adam Burdorf; Yael Potashnik-Peled; Michael J. Moulton; John Um; E. Raichlin
Background: Depression and anxiety are associated with a worse prognosis in heart failure patients. The aim of this study was to identify the prevalence of depression and anxiety in left ventricular assist device (LVAD) candidates and assess their effect on post-LVAD outcomes. Methods: Based on the pre-LVAD psychological assessment, the total cohort of 246 patients were divided into 4 groups: 1) no depression or anxiety (NDep&Anx group, n = 138); 2) isolated depression (Dep group, n = 42); 3) isolated anxiety (Anx group, n = 32), and 4) combined depression and anxiety (Dep&Anx group, n = 34). Results: The Dep&Anx group was associated with higher prevalence of female gender (p = 0.03), higher body mass index (p = 0.03), elevated E/E’ (p = 0.003), and increased Model For End-Stage Liver Disease (MELD) XI score (p = 0.04) prior to LVAD as compared to the other 3 subgroups. The prevalence of other major psychiatric disorders (p = 0.03) and narcotic dependence (p = 0.004) was higher in the Dep&Anx group. Post-LVAD implantation, heart rate and filling pressures were elevated and readmission rate was higher (p = 0.001) in the Dep&Anx group. There was no difference in survival between the groups (p = 0.40, Log-Rank test). Conclusions: Pre-existing anxiety and depression was associated with worse HF pre- and post-LVAD implantation and higher readmissions rate after LVAD implantation.
Heart Lung and Circulation | 2018
A. Selim; Lalit Wadhwani; Adam Burdorf; Eugenia Raichlin; Brian D. Lowes; Ronald Zolty
BACKGROUND Pulmonary hypertension secondary to left heart disease (WHO Group 2) is a known risk factor in patients with heart failure. The favourable effect of left ventricular assist devices (LVAD) on pulmonary hypertension has been demonstrated before, although this effect has not been well-studied in advanced pulmonary arterial bed disease with a significant elevation in pulmonary vascular resistance. METHODS We reviewed the records of 258 LVAD patients in our institution. Patients with elevated mean pulmonary artery pressure (mPAP>25mmHg) and elevated pulmonary vascular resistance (PVR ≥3 Wood units) were included in the study. Patients were divided into two groups based on their baseline PVR (PVR=3-5 Wood units (WU) vs. PVR>5WU). The groups were studied for the changes in their pulmonary haemodynamics after the placement of LVAD. RESULTS Fifty-one (51) patients were included in the study. All patients showed a significant improvement in their pulmonary haemodynamic parameters post LVAD placement. In the group with the higher PVR, mPAP dropped from a baseline of 43±7mmHg to 22±6mmHg post LVAD placement (p<0.001), while PVR dropped from 6.3±1.2 Wood units to 2.2±1.1 Wood units (p<0.001). In a subgroup of patients who underwent cardiac transplantation post LVAD (n=14), all patients maintained a normalised PVR (<3WU) one year post cardiac transplantation. CONCLUSIONS Left ventricular assist devices can reverse pulmonary hypertension WHO Group 2 with significantly elevated PVR; this effect is not dependent on the baseline PVR, and is maintained up to one year post cardiac transplantation.
Clinical Transplantation | 2017
Sara Varnado; Yael Peled-Potashnik; Ashley Huntsberry; Brian D. Lowes; Ronald Zolty; Adam Burdorf; Elizabeth Lyden; Michael J. Moulton; John Um; Eugenia Raichlin
Sinus tachycardia (ST) is common after heart transplantation (HTx). The aim of the study was to evaluate the effect of diltiazem treatment during the first year after HTx on heart rate (HR), cardiac allograft function, and exercise capacity.
Journal of the American College of Cardiology | 2016
Eugenia Raichlin; Sara Varnado; Adam Burdorf; Ashley Huntsberry; Brian D. Lowes; Ronald Zolty; H. Vongooru; Brook Fenske; A. Siddique; Michael J. Moulton; John Um
Exercise performance, an important aspect of quality of life, remains limited after heart transplantation (HTx). Sinus tachycardia often presents in HTx recipients, but its effect on functional capacity remains unknown. Based on heart rate (HR) 3 months after HTx, 198 patients transplanted from
Journal of Cardiac Failure | 2015
Nicholas A. Haglund; Adam Burdorf; Tara Jones; Valerie Shostrom; John Um; Timothy Ryan; Sasha K. Shillcutt; Patricia Fischer; Zachary L. Cox; Eugenia Raichlin; Brian D. Lowes; Ioana Dumitru
Asaio Journal | 2017
Scott Lundgren; Brian D. Lowes; Ronald Zolty; Adam Burdorf; Eugenia Raichlin; John Um; Cecilia Poon
Journal of the American College of Cardiology | 2018
Arif Albulushi; Marshall Hyden; Douglas Stoller; Adam Burdorf; Ronald Zolty; Brian D. Lowes; John Um; Jeffrey W. Delaney
Journal of the American College of Cardiology | 2018
Scott Lundgren; Elizabeth Lyden; Adam Burdorf; Marshall Hyden; Douglas Stoller; Ronald Zolty; John Um; Brian D. Lowes
Journal of the American College of Cardiology | 2018
Scott Lundgren; Elizabeth Lyden; Adam Burdorf; Marshall Hyden; Douglas Stoller; Ronald Zolty; John Um; Brian D. Lowes